Skip to main content

Table 3 Univariate and multivariate cox regression analysis

From: Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India

Variable

Univariate

Multivariate

HR

95%CI

P value

HR

95%CI

P value

Age

1.017

1.002–1.032

0.029

1.012

0.994–1.029

0.200

Male Sex

0.813

0.577–1.145

0.237

   

Hypertension

0.887

0.638–1.233

0.476

   

Diabetes

0.983

0.714–1.353

0.916

   

Obesity

0.805

0.435–1.489

0.489

   

Other comorbidities

0.926

0.487–1.761

0.815

   

Number of comorbidities

1.090

0.903–1.315

0.371

   

Oxygen saturation

0.979

0.962–0.996

0.017

0.969

0.950–0.989

0.002

CRP

0.999

0.996–1.002

0.379

   

Creatinine

1.157

1.031–1.298

0.013

1.123

0.995–1.267

0.061

Respiratory rate

1.045

1.006–1.084

0.023

   

LDH

1.000

0.997–1.003

0.880

   

Ferritin

1.000

1.000–1.001

0.626

   

D-dimer

1.000

1.000–1.000

0.043

   

WBC counts

1.000

1.000–1.000

0.875

   

Tocilizumab

0.655

0.476–0.901

0.009

0.621

0.427–0.903

0.013

CT severity score

1.084

0.810–1.449

0.588

   

Thrombosis

2.160

0.135–34.608

0.586

   

Non-invasive ventilation

0.770

0.525–1.131

0.183

   

Invasive ventilation

2.028

1.349–3.049

0.001

2.31

1.442–3.701

0.001

  1. Data on respiratory rate was available only for 142 patients while d-dimer was available for 78 patients. Hence these parameters were not included in the multivariate analysis
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us